Oral Oncology

Papers
(The H4-Index of Oral Oncology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Prognostic impact of socioeconomic status compared to overall stage for HPV-negative head and neck squamous cell carcinoma308
Inter-assay reliability of programmed cell death-ligand 1 in head and neck squamous cell carcinoma95
Reflectance confocal microscopy (RCM)-based criteria for progression of lower-lip squamous cell carcinoma: A prospective study64
Combined Pik3ca-H1047R and loss-of-function Notch1 alleles decrease survival time in a 4-nitroquinoline N-oxide-driven head and neck squamous cell carcinoma model56
Authors reply to the comment on: Association of sarcopenia with oncologic outcomes of primary treatment among patients with oral cavity cancer: A systematic review and meta-analysis55
Radiation-induced osteosarcoma in the head and neck region: Case report and literature review47
Comments on the article titled “Factors associated with unknown primary status in head and neck squamous cell carcinoma”: Is the N status the overlooked elephant in the room?45
A single-cell sequencing-based analysis of a 13-year-old with maxillary sinus NUT carcinoma45
Revaluation of the treatment of head and neck cancer in Brazil during the COVID-19 pandemic - phase 243
P-167 Comparison of Clinical and Pathological Staging in Patients with Head and Neck Cancer After Elective Neck Dissection42
Editorial Board/Aims & Scope39
P28 Head and neck cancer cells differentiate resembling their tissue of origin37
P-86 Tumor Recurrence on Pectoralis Major Myocutaneous Flap35
The characteristics and prospects of reflectance confocal microscopy for noninvasive diagnosis of oral potentially malignant disorders33
Salvage Treatment in Isolated Regional Recurrent Head and Neck Squamous Cell Carcinoma33
Corrigendum to salivary microRNA- 375: A novel biomarker in the malignant transformation of oral potentially malignant disorders [Oral Oncol. 134 (2022) 106065]32
P-140 Clinical outcomes following pharyngolaryngectomy reconstruction: a 20-year single centre study32
P-72 Hypofractionated, Dose redistributed RAdiotherapy for head and neck squamous cell carcinoma (HYDRA)31
P-22 Artifact reduction in head and neck CT images using polyetheretherketone (PEEK), polyetherketoneketone (PEKK), polyphenylsulfone (PPSU) and polyether (PE) polymer implants in mandible reconstruct31
“Haemophilia A” – Presenting with oral squamous cell carcinoma diagnosis and management strategies31
Comment on “Extensive necrosis of the tongue as a very early adverse event of head and neck radiotherapy”30
Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study30
The Role of microRNAs as a predictive biomarker and therapeutic molecule in the treatment of Oral Potentially Malignant Disorder (OPMD)29
Restoring the anti-tumor property of PTEN: A promising oral cancer treatment29
Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection28
Clinicopathological factors associated with progression of oral submucous fibrosis: A population-based retrospective study28
Sentinel lymph node biopsy in recurrent or secondary oral squamous cell carcinoma after previous neck dissection28
The effect of skeletal muscle mass on dose-limiting toxicities during (chemo)radiotherapy in patients with head and neck cancer: A systematic review and meta-analysis28
0.24949193000793